雾化硫酸镁对急性哮喘:一项系统回顾。

文章的细节

引用

复制到剪贴板

闪电战,闪电战,休斯R,用餐者B,比斯利R, Knopp J,罗威黑洞

雾化硫酸镁对急性哮喘:一项系统回顾。

胸部。2005年7月,128 (1):337 - 44。

PubMed ID

16002955 (在PubMed

]

文摘

背景:使用MgSO(4)是众多的治疗选择之一在哮喘急性加重。虽然治疗的疗效与静脉MgSO(4)已经证明,对吸入MgSO (4)。目的:系统回顾文献进行检查的影响吸入MgSO(4)治疗哮喘急性加重患者在急诊科。方法:随机对照试验是合格的包容和被确定Cochrane航空集团“哮喘和Wheez *”登记,由一个联合搜索EMBASE,中央,MEDLINE, CINAHL数据库和手动搜索20键呼吸期刊。必威国际app参考列表发表的研究都是搜索和灰色文献的回顾也执行。必威国际app研究包括如果病人已经接受喷雾MgSO(4)单独或结合β(2)受体激动剂相比,使用β(2)受体激动剂单独或与一个不活动的控制物质。试验选择、数据提取和方法学质量评估由两个独立的评论家。固定后果模型的结果作为标准均数差值(smd)肺功能和相对风险(RRs)住院。两者都显示他们的95%置信区间(CIs)。结果:6个试验包括296名患者。 There was a non-significant increase [corrected] in pulmonary function between patients whose treatments included nebulized MgSO(4) and those whose treatments [corrected] did not (SMD, 0.22; 95% CI, -0.02 to 0.47 [corrected] five studies); there was also a trend toward reduced [corrected] hospitalizations in patients whose treatments included nebulized MgSO(4) (RR, 0.67; 95% CI, 0.41 to 1.09; four studies). Subgroup analyses demonstrated that lung function improvement was similar in adult patients and in those patients who received nebulized MgSO(4) in addition to a beta(2)-agonist. CONCLUSIONS: The use of nebulized MgSO(4), particularly in addition to a beta(2)-agonist, in the treatment of an acute asthma exacerbation appears to produce benefits with respect to improved pulmonary function and may reduce the number of hospital admissions.

DrugBank数据引用了这篇文章

药物

硫酸镁